Long
Tetra Bio Pharma - Strong Buy - Extended Bull Run
Tetra Bio Pharma -2.85% is our pick of the Week. Oversold, primed for legalization with commercialization, and a cluster bomb of promising clinical trials. So when will this extended bull run begin? Our analysis shows us, the extended bull run will start tomorrow. Volume was last seen lowest on June 5th, 2018, and has been slowly but steadily increasing, along with the SP -1.55% . Although, no price action is seen above .74$ per share, we believe this will be short lived coming into July, 2018. Here, we expect to top off at .88$ per share, with a bottom of .76$ ps, this will be followed with a continued rally up and beyond legalization. This will be supported by commercialization deals made with previously announced and unannounced distributors. Known catalysts for short term prospective s have North Bud IPO next month that should garner some attention. We expect Tetra bio-pharma to be in Blue sky territory in/around July 16th to July 27th, 2018. We do have a fair market estimation, based on companies efficiencies of a cash burn rate of 110,000$ month and with potential sales potential of 10- 30 million$ forward (2019); 50 - 80 million$ forward (2020). Subsequently, fair market price for tetra Bio pharma -2.85% currently sits at 1.15$ per share; 2.30$ ps forward 18 X p/e (2019); 4.25$ forward (2020).We expect clinical trials to be successful as historical data clearly shows a promising correlation between ratios of thc/cbd that can effectively tx -1.20% pain. Subsequently, THIS IS THE KICKER! SUCCESSFUL TRIALS OF RxPRINCEPS WILL GARNISH AND EXPEDITE OTHER CLINICAL TRIALS IN THEIR PIPELINE, THUS COMPOUNDING SHARE HOLDER VALUE. WE DO FEEL THE BOTTOM HAS BEEN REACHED, AND A PROGRESSIVE INCREASE IN SP -1.55% WILL FOLLOW BEYOND LEGALIZATION.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.